Sooma [ENG]

Non-invasive brain stimulation device, a treatment option for depression and chronic pain

Sooma Oy is developing, manufacturing and marketing a non-invasive therapy device for neurological and psychiatric disorders (depression and chronic pain). Sooma uses transcranial direct current stimulation (tDCS) technology. Sooma technology is trusted by over 100 clinics worldwide. Their first product is the first portable device approved for treatment of major depressive disorder (MDD). The device is CE-approved and currently marketed in the EU and other selected markets. Their quality management system has been awarded with ISO 13485:2016 and MDSAP certificates.


[Scheda startup - Blocco Champions] Lorem ipsum

"I would like to thank Athensmed and Italian Angels for Growth for demonstrating their trust in Sooma with this investment, as well as our previous investors for their support in our mission. We are also thankful for Business Finland for their continued support. Our solution, a medication-free treatment for clinical depression, is already improving the standard of care and reducing costs in the most forward-looking care centers in Europe and other selected markets. This newest funding will help us to reach the next milestone in our journey as the leading provider of home-based neuromodulation therapies".

 Tuomas Neuvonen


Notizie correlate

SOOMA closes an investment round of over 1.2 Million EUR

Thanks to the capital increase from IAG members and Athensmed, the startup aims to take its drug-free therapy for depression to worldwide market.